Yazan Madanat, MD, comments on the updates that were recently presented at ASH 2023 for the management of lower-risk MDS and discusses the impact of emerging therapies.
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More